Background: Laparoscopic single anastomosis sleeve ileal (SASI) bypass has recently evolved as a novel approach to
treating both obesity and its associated comorbidities. This study aims to evaluate the efficacy and feasibility of SASI
bypass in patients with obesity and type 2 diabetes mellitus (T2DM).
Patients and Methods: We conducted a prospective study on 30 morbidly obese patients having T2DM between January
2021 to September 2022. All the patients underwent laparoscopic SASI bypass, and all were followed for 12 months after
surgery in terms of T2DM remission. Other parameters were also recorded and analyzed. The percentage of mean excess
weight loss (EWL%) was evaluated and noted at each follow-up.
Results: At 12 months, EWL% was 82%. All the patients evaluated had shown T2DM remission by 1 year (6.7% partial
remission and 93.3% complete remission), with 77.8% remission of hypertension and 95.5% remission of dyslipidemia.
Conclusion: SASI offers an excellent EWL% reduction, T2DM remission, and comorbidities resolution, and it should be
considered an effective way to treat obesity in T2DM.